Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

1.

Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.

Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.

J Immunother. 2012 Oct;35(8):629-40.

PMID:
22996369
[PubMed - indexed for MEDLINE]
2.

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.

Plate JM, Plate AE, Shott S, Bograd S, Harris JE.

Cancer Immunol Immunother. 2005 Sep;54(9):915-25. Epub 2005 Mar 22.

PMID:
15782312
[PubMed - indexed for MEDLINE]
3.

Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.

Bellone G, Novarino A, Vizio B, Brondino G, Addeo A, Prati A, Giacobino A, Campra D, Fronda GR, Ciuffreda L.

Int J Oncol. 2009 Jun;34(6):1701-15.

PMID:
19424589
[PubMed - indexed for MEDLINE]
4.

The pemetrexed/gemcitabine combination in pancreatic cancer.

Kindler HL.

Cancer. 2002 Aug 15;95(4 Suppl):928-32. Review.

PMID:
12209673
[PubMed - indexed for MEDLINE]
Free Article
5.

Pemetrexed in pancreatic cancer.

Seitz JF, Dahan L, Ries P.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):43-7. Review.

PMID:
15655936
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.

J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.

PMID:
18506025
[PubMed - indexed for MEDLINE]
Free Article
7.

Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.

Lee SK, Kim JY, Jang BW, Hur SE, Na BJ, Lee M, Fukui A, Gilman-Sachs A, Kwak-Kim J.

Hum Immunol. 2011 Aug;72(8):621-6. doi: 10.1016/j.humimm.2011.03.013. Epub 2011 May 11.

PMID:
21600259
[PubMed - indexed for MEDLINE]
8.

Pemetrexed in pancreatic cancer.

Kindler HL.

Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. Review.

PMID:
12571811
[PubMed - indexed for MEDLINE]
9.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL.

Ann Oncol. 2005 Oct;16(10):1639-45. Epub 2005 Aug 8. Erratum in: Ann Oncol. 2006 Mar;17(3):535.

PMID:
16087696
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

PMID:
22474386
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.

PMID:
18349397
[PubMed - indexed for MEDLINE]
Free Article
13.

Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.

Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK.

Lung Cancer. 2006 Jul;53(1):77-83. Epub 2006 May 30.

PMID:
16730854
[PubMed - indexed for MEDLINE]
14.

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.

von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G, Kania M.

Ann Oncol. 2006 Oct;17(10):1533-8. Epub 2006 Jul 27.

PMID:
16873433
[PubMed - indexed for MEDLINE]
Free Article
15.

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.

Comella P, Chiuri VE, De Cataldis G, Filippelli G, Maiorino L, Vessia G, Cioffi R, Mancarella S, Putzu C, Greco E, Palmeri L, Costanzo R, Avallone A, Franco L.

Lung Cancer. 2010 Apr;68(1):94-8. doi: 10.1016/j.lungcan.2009.05.008. Epub 2009 Jul 9.

PMID:
19545929
[PubMed - indexed for MEDLINE]
16.

Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.

De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F.

J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818.

PMID:
21336182
[PubMed - indexed for MEDLINE]
17.

Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer.

Bang S, Kim HS, Choo YS, Park SW, Chung JB, Song SY.

Pancreas. 2006 Jan;32(1):29-36.

PMID:
16340741
[PubMed - indexed for MEDLINE]
18.

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P.

Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25.

PMID:
19473833
[PubMed - indexed for MEDLINE]
19.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
[PubMed - indexed for MEDLINE]
Free Article
20.

NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.

Cosiski Marana HR, Santana da Silva J, Moreira de Andrade J.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):318-23.

PMID:
10985887
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk